Evidence from the UK: Improving SOPs and management of patients with chronic obstructive pulmonary disease in primary healthcare
Chronic obstructive pulmonary disease (COPD) is a common and preventable condition that affects the lungs and causes breathing difficulties. It is estimated that 1.2 million people in the UK are living with diagnosed COPD, making it the second most common lung disease after asthma . COPD is mainly caused by smoking, but other factors such as air pollution, occupational exposure, genetics and infections can also contribute to its development . COPD can have a significant impact on the quality of life and health outcomes of patients, as well as imposing a substantial burden on the healthcare system .
The management of COPD in primary healthcare is crucial for preventing disease progression, reducing exacerbations, improving symptoms and enhancing patient satisfaction. However, there are challenges and gaps in the delivery of optimal care for COPD patients in primary care settings, such as lack of awareness, diagnosis, education, self-management support, adherence to guidelines and coordination of care . Therefore, there is a need to improve the standard operating procedures (SOPs) and management of COPD patients in primary healthcare, based on the best available evidence and practice.
This blog post aims to provide an overview of the current evidence and recommendations for improving SOPs and management of COPD patients in primary healthcare in the UK. It will cover the following topics:
– Diagnosis and assessment of COPD
– Pharmacological and non-pharmacological treatments for COPD
– Self-management and education for COPD patients
– Monitoring and follow-up of COPD patients
– Coordination and integration of care for COPD patients
Diagnosis and assessment of COPD
The diagnosis of COPD is based on the presence of persistent respiratory symptoms (such as breathlessness, cough, wheeze or sputum production) and airflow limitation (measured by spirometry) that is not fully reversible . Spirometry is a simple and reliable test that measures how much air a person can breathe out in one second (forced expiratory volume in one second or FEV1) and how much air they can breathe out in total (forced vital capacity or FVC). The ratio of FEV1 to FVC (FEV1/FVC) indicates the degree of airflow obstruction. A FEV1/FVC ratio below 0.7 confirms the diagnosis of COPD .
Spirometry should be performed in primary care settings for all patients who have symptoms suggestive of COPD, especially if they are over 35 years old and have a history of smoking or exposure to other risk factors . Spirometry should also be repeated periodically to monitor disease progression and response to treatment . However, spirometry is not widely available or used in primary care settings in the UK, leading to underdiagnosis or misdiagnosis of COPD . Therefore, there is a need to increase the availability, accessibility and quality of spirometry services in primary care settings, as well as to train and educate primary care staff on how to perform and interpret spirometry results correctly .
In addition to spirometry, the assessment of COPD patients should include a comprehensive history taking, physical examination, assessment of symptoms severity, impact on daily activities and quality of life, comorbidities, exacerbation history and risk factors . These assessments can help to determine the appropriate treatment plan and follow-up schedule for each patient. Several tools can be used to facilitate these assessments, such as the Medical Research Council (MRC) dyspnoea scale, the COPD Assessment Test (CAT), the Clinical COPD Questionnaire (CCQ), the modified British Medical Research Council (mMRC) questionnaire, the COPD exacerbation frequency questionnaire (EXAcerbations of Chronic pulmonary disease Tool or EXACT), the Charlson comorbidity index (CCI) and the BODE index (which combines body mass index, airflow obstruction, dyspnoea and exercise capacity) .
Pharmacological and Non-Pharmacological Treatments for COPD
==========================================================
Chronic obstructive pulmonary disease (COPD) is a common and preventable condition that affects the lungs and causes breathing difficulties. It is usually caused by smoking, but can also be triggered by environmental factors, genetic factors or poor lung development. COPD can lead to complications such as heart failure, depression, anxiety and respiratory failure. The main goals of treatment are to relieve symptoms, improve exercise tolerance, reduce exacerbations and improve health status and quality of life.
Pharmacological Treatments
————————–
Pharmacological treatments for COPD include inhalers, tablets and nebulisers that help to open up the airways, reduce inflammation and prevent infections. The choice of medication depends on the severity of the condition, the frequency of exacerbations and the patient’s preference and ability to use the device. Some of the common types of pharmacological treatments are:
– Bronchodilators: These are drugs that relax the muscles around the airways and make breathing easier. They can be short-acting or long-acting, depending on how long they last in the body. Examples of bronchodilators are salbutamol, ipratropium, tiotropium, indacaterol and olodaterol.
– Corticosteroids: These are drugs that reduce inflammation and swelling in the airways. They can be inhaled or taken orally, depending on the severity of the condition. Examples of corticosteroids are budesonide, fluticasone, prednisolone and methylprednisolone.
– Antibiotics: These are drugs that treat bacterial infections that can cause or worsen COPD exacerbations. They can be taken orally or intravenously, depending on the type and severity of the infection. Examples of antibiotics are amoxicillin, doxycycline, azithromycin and levofloxacin.
– Mucolytics: These are drugs that thin the mucus in the airways and make it easier to cough up. They can be taken orally or inhaled, depending on the formulation. Examples of mucolytics are acetylcysteine, carbocisteine and erdosteine.
– Phosphodiesterase-4 inhibitors: These are drugs that reduce inflammation and relax the muscles around the airways. They can be taken orally as tablets. An example of a phosphodiesterase-4 inhibitor is roflumilast.
Non-Pharmacological Treatments
——————————
Non-pharmacological treatments for COPD include lifestyle changes, pulmonary rehabilitation, oxygen therapy and surgery. These interventions aim to improve the patient’s physical and mental well-being, reduce risk factors and prevent complications. Some of the common types of non-pharmacological treatments are:
– Smoking cessation: This is the most important and effective intervention for COPD patients who smoke. Smoking damages the lungs and worsens the condition. Quitting smoking can improve symptoms, lung function, quality of life and survival. Smoking cessation can be achieved with behavioural support, nicotine replacement therapy, medication or a combination of these methods.
– Pulmonary rehabilitation: This is a specialised programme of exercise and education that helps COPD patients to cope with their condition and improve their physical and mental health. Pulmonary rehabilitation involves supervised exercise training, breathing techniques, disease education, nutritional advice, psychological support and social interaction. Pulmonary rehabilitation can improve symptoms, exercise capacity, quality of life and reduce hospital admissions.
– Oxygen therapy: This is a treatment that provides supplemental oxygen to COPD patients who have low blood oxygen levels. Oxygen therapy can be delivered through nasal prongs or a mask, either at home or in a hospital setting. Oxygen therapy can improve symptoms, exercise tolerance, quality of life and survival in some patients with severe COPD.
– Surgery: This is a treatment that involves removing damaged parts of the lungs or replacing them with healthy ones from a donor. Surgery is only an option for a very small number of patients with severe COPD who have not responded to other treatments. Types of surgery include lung volume reduction surgery (LVRS), bullectomy and lung transplantation.
Conclusion
———-
COPD is a chronic condition that affects millions of people worldwide. It can cause significant morbidity and mortality if left untreated or poorly managed. Pharmacological and non-pharmacological treatments can help to control symptoms, improve function, prevent complications and enhance quality of life for COPD patients. The choice of treatment should be individualised according to the patient’s needs, preferences and goals.
References
———-
[NICE (2019). Chronic obstructive pulmonary disease in over 16s: diagnosis and management (NG115).](https://www.nice.org.uk/guidance/ng115)
[BNF (2021). Chronic obstructive pulmonary disease assignment help – research paper writing service.](https://bnf.nice.org.uk/treatment-summaries/chronic-obstructive-pulmonary-disease/)
[NHS (2019). Chronic obstructive pulmonary disease (COPD) – Treatment.](https://www.nhs.uk/conditions/chronic-obstructive-pulmonary-disease-copd/treatment/)
[COPD News Today (2017). Non-Pharmacological Treatments for COPD.](https://copdnewstoday.com/copd-treatment/non-pharmacological-treatments/)
[Springer (2019). Pharmacological and non-pharmacological management of COPD; limitations and perspectives.](https://link.springer.com/article/10.1007/s10389-019-01021-3)
